icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of Tenofovir Alafenamide at 96 Weeks in Chronic HBV Patients With Risk Factors for Use of Tenofovir Disoproxil Fumarate
 
 
  Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
 
Maria Buti,1 Tatjana Stepanova,2 Mustafa K. Celen,3 Robert Flisiak,4 Stephen D. Ryder,5 Adrian Streinu-Cercel,6 Selim Gurel,7 John F. Flaherty,8 Anuj Gaggar,8 Vithika Suri,8 Shuyuan Mo,8 Mani Subramanian,8 Elena Nurmukhametova,9 Fabien Zoulim,10 Pietro Andreone,11 Patrick Marcellin12
1Vall d'Hebron Barcelona Campus Hospitalari, Barcelona, Spain; 2Modern Medicine Clinic, Moscow, Russia; 3Dicle Universitesiy Hospital, Diyarbakir, Turkey; 4Uniwersytet Medyczny w Biaymstoku, Poland; 5Nottingham University Hospitals, Nottingham, UK; 6Universitatea de Medicina si Farmacie "Carol Davila" din Bucuresti, Romania; 7Uludag Universitesi Tip Fakultesi, Bursa, Turkey; 8Gilead Sciences, Inc., Foster City, CA; 9Infectious Clinical Hospital 1 of Moscow Healthcare Dept, Russia; 10Hopital de la Croix Rousse, Lyon, France; 11Universita di Bologna, Italy; 12Service d'Hépatologie, INSERM CRI, Université Paris Diderot, Hopital Beaujon, Clichy, France

AASDL1

AASDL2

AASDL3

AASDL4

AASDL5

AASDL6

AASDL7

References
 
1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Agarwal K, et al. EASL 2017, poster FRI-153; 6. Brunetto M, et al. EASL 2017, abstr PS-042; 7. Buti M, et al. Lancet Gastroenterol Hepatol 2016;1:196-206; 8. Chan HLY, et al. Lancet Gastroenterol Hepatol 2016;1:185-95; 9. European Association for the Study of the Liver. J Hepatol. 2017;67:370-98; 10. Terrault NA, et al. Hepatology 2016;63:261-83.